Hepatitis B virus (HBV) causes a life threat to the liver, often leading to chronic infection throughout a lifetime. Each year, HBV has caused 887,000 deaths, most of them due to chronic hepatocellular carcinoma and liver illnesses. There are about 250 million chronic carriers around the world that are at high risk for hepatocellular carcinoma or cirrhosis (HCC). HCC has a high relationship with HBV infection and is also the most frequent form of liver cancer. The common modes of infection have been HBV transmission through blood transfusions and perinatal transfer from infected mother to child.
In this study the researchers have described the invention and capacity of this platform to control in vivo antibody expression of a synthetic DNA plasmid which encodes a human monoclonal antibody specific to the common “determinant region” for Hepatitis B-virus HBsAg. The key conformational epitopes for plasma isolated natural HBsAg and bound HBV in HepG2.2.15 cells have been discovered to be recognised by serum antibody. Serum DMAb neutralised HBV effectively and stopped HepaRG cells from becoming infected in vitro. A further study is necessary of this HBV-DMAb as feasible for HBV infection therapy or immune prophylaxis.
Reference: https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1763686
